{"id":229628,"date":"2026-09-03T15:28:45","date_gmt":"2026-09-03T09:58:45","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=229628"},"modified":"2026-09-03T15:28:48","modified_gmt":"2026-09-03T09:58:48","slug":"piramal-pharma-share-bull-case-vs-bear-case-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/","title":{"rendered":"Piramal Pharma Share: Bull Case vs Bear Case for 2026"},"content":{"rendered":"<div class=\"meta-block\">\u00a0<\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Piramal Pharma CMP Rs 215.39 on 3 Sep 2026. 52W High Rs 220.36, Low Rs 132.30. PE not meaningful (loss making) vs sector 37.95. RSI 60.13.<\/em><\/p>\n<div style=\"background: #F0F9FF; border-left: 4px solid #2E7D32; border-radius: 6px; padding: 14px 18px; margin: 18px 0;\">\n<p style=\"margin: 0; color: #1f4e79; font-size: 14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin: 8px 0 0;\">The Piramal Pharma bull case for 2026 points toward the stock retesting its 52 week high of Rs 220.36, built on the strengths discussed below. The Piramal Pharma bear case points toward a slide back near its 52 week low of Rs 132.30 if the risks play out instead. The stock currently trades at Rs 215.39, with a loss making bottom line, so the industry average PE of 37.95 is the reference point for any future re-rating. The next two quarters of earnings and sector data will likely decide which case plays out.<\/p>\n<\/div>\n<p>The Piramal Pharma bull case is under the spotlight as investors weigh Piramal Pharma&#8217;s recent price action against its underlying fundamentals. The stock trades at Rs 215.39, against a 52 week high of Rs 220.36 and a 52 week low of Rs 132.30, leaving room for both the Piramal Pharma bull case and the Piramal Pharma bear case to find support in the data.<\/p>\n<p>Piramal Pharma operates in the Pharmaceuticals and CDMO space, and its return on equity of -3.58 percent and debt to equity ratio of 0.70 form the backbone of the fundamental picture. This article lays out the full Piramal Pharma bull case and bear case, the data behind each scenario, and the catalysts that could tip the balance one way or the other.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=pplpharma_bull_bear_2026\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#Piramal_Pharma_Company_Overview\" title=\"Piramal Pharma Company Overview\">Piramal Pharma Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#The_Piramal_Pharma_Bull_Case\" title=\"The Piramal Pharma Bull Case\">The Piramal Pharma Bull Case<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#Strong_Momentum_Near_52_Week_High\" title=\"Strong Momentum Near 52 Week High\">Strong Momentum Near 52 Week High<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#Diversified_Pharma_and_CDMO_Portfolio\" title=\"Diversified Pharma and CDMO Portfolio\">Diversified Pharma and CDMO Portfolio<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#Global_CDMO_Manufacturing_Footprint\" title=\"Global CDMO Manufacturing Footprint\">Global CDMO Manufacturing Footprint<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#Narrowing_Losses\" title=\"Narrowing Losses\">Narrowing Losses<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#The_Piramal_Pharma_Bear_Case\" title=\"The Piramal Pharma Bear Case\">The Piramal Pharma Bear Case<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#Currently_Loss_Making\" title=\"Currently Loss Making\">Currently Loss Making<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#Leveraged_Balance_Sheet\" title=\"Leveraged Balance Sheet\">Leveraged Balance Sheet<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#Regulatory_and_Quality_Compliance_Risk\" title=\"Regulatory and Quality Compliance Risk\">Regulatory and Quality Compliance Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#Segment_Integration_Complexity\" title=\"Segment Integration Complexity\">Segment Integration Complexity<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#Piramal_Pharma_Bull_vs_Bear_Scenario_Table\" title=\"Piramal Pharma Bull vs Bear Scenario Table\">Piramal Pharma Bull vs Bear Scenario Table<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#What_Could_Tip_the_Balance_Between_the_Bull_and_Bear_Case\" title=\"What Could Tip the Balance Between the Bull and Bear Case\">What Could Tip the Balance Between the Bull and Bear Case<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#How_to_Invest_in_Piramal_Pharma\" title=\"How to Invest in Piramal Pharma\">How to Invest in Piramal Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#FAQs_on_Piramal_Pharma_Bull_Case_vs_Bear_Case\" title=\"FAQs on Piramal Pharma Bull Case vs Bear Case\">FAQs on Piramal Pharma Bull Case vs Bear Case<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#What_is_the_Piramal_Pharma_bull_case_for_2026\" title=\"What is the Piramal Pharma bull case for 2026?\">What is the Piramal Pharma bull case for 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#What_is_the_Piramal_Pharma_bear_case_for_2026\" title=\"What is the Piramal Pharma bear case for 2026?\">What is the Piramal Pharma bear case for 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#Should_I_buy_Piramal_Pharma_share_now\" title=\"Should I buy Piramal Pharma share now?\">Should I buy Piramal Pharma share now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#What_are_the_key_risks_in_the_Piramal_Pharma_bear_case\" title=\"What are the key risks in the Piramal Pharma bear case?\">What are the key risks in the Piramal Pharma bear case?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#What_are_the_main_catalysts_for_the_Piramal_Pharma_bull_case\" title=\"What are the main catalysts for the Piramal Pharma bull case?\">What are the main catalysts for the Piramal Pharma bull case?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#Where_can_I_track_Piramal_Pharma_share_price_live\" title=\"Where can I track Piramal Pharma share price live?\">Where can I track Piramal Pharma share price live?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#What_is_the_52_week_high_and_low_of_Piramal_Pharma\" title=\"What is the 52 week high and low of Piramal Pharma?\">What is the 52 week high and low of Piramal Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-bull-case-vs-bear-case-2026\/#How_can_I_buy_Piramal_Pharma_shares\" title=\"How can I buy Piramal Pharma shares?\">How can I buy Piramal Pharma shares?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Piramal_Pharma_Company_Overview\"><\/span><strong>Piramal Pharma Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse: collapse; width: 100%;\" border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<td><strong>Metric<\/strong><\/td>\n<td><strong>Value<\/strong><\/td>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td><a href=\"https:\/\/univest.in\/stocks\/pplpharma\/piramal-pharma-share-price-today\">Piramal Pharma<\/a> (PPLPHARMA)<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Pharmaceuticals and CDMO<\/td>\n<\/tr>\n<tr>\n<td>CMP<\/td>\n<td>Rs 215.39<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 220.36<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 132.30<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 28,444 Crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio<\/td>\n<td>not meaningful (loss making) (Industry PE 37.95)<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>-3.58 percent<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.70<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Piramal Pharma reports earnings per share of Rs -2.36, a book value of Rs 61.34 per share and a dividend yield of 0.00 percent at the current price. These fundamentals form the base data behind the Piramal Pharma bull case discussed below.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"The_Piramal_Pharma_Bull_Case\"><\/span><strong>The Piramal Pharma Bull Case<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Strong_Momentum_Near_52_Week_High\"><\/span><strong>Strong Momentum Near 52 Week High<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The stock trades well above both its 50 day moving average of Rs 193.86 and 200 day moving average of Rs 181.24, close to its 52 week high, reflecting improving investor sentiment.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Diversified_Pharma_and_CDMO_Portfolio\"><\/span><strong>Diversified Pharma and CDMO Portfolio<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A presence across CDMO manufacturing, complex hospital generics and consumer healthcare gives Piramal Pharma multiple growth avenues beyond a single business line.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Global_CDMO_Manufacturing_Footprint\"><\/span><strong>Global CDMO Manufacturing Footprint<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>An established contract development and manufacturing footprint across India, the US and Europe gives the company scale advantages in a segment with high barriers to entry.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Narrowing_Losses\"><\/span><strong>Narrowing Losses<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A return on equity of negative 3.58 percent, while still negative, reflects a business that has been moving closer to breakeven as its CDMO and consumer healthcare segments scale.<\/p>\n<p>Taken together, these factors form the core of the Piramal Pharma bull case for the stock.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"The_Piramal_Pharma_Bear_Case\"><\/span><strong>The Piramal Pharma Bear Case<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Currently_Loss_Making\"><\/span><strong>Currently Loss Making<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The company reported negative earnings per share of Rs 2.36, meaning the business has not yet returned to sustained profitability.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Leveraged_Balance_Sheet\"><\/span><strong>Leveraged Balance Sheet<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A debt to equity ratio of 0.70 adds interest rate sensitivity on top of the current loss making position.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Regulatory_and_Quality_Compliance_Risk\"><\/span><strong>Regulatory and Quality Compliance Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>As a pharmaceutical manufacturer serving regulated markets, the company remains exposed to regulatory inspection outcomes at its facilities.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Segment_Integration_Complexity\"><\/span><strong>Segment Integration Complexity<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Managing a diversified portfolio spanning CDMO, hospital generics and consumer healthcare adds operational complexity compared to a more focused pharmaceutical business.<\/p>\n<p>Weighed against the Piramal Pharma bull case, these risks are what could keep the stock anchored closer to its recent lows.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Piramal_Pharma_Bull_vs_Bear_Scenario_Table\"><\/span><strong>Piramal Pharma Bull vs Bear Scenario Table<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse: collapse; width: 100%;\" border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<td><strong>Scenario<\/strong><\/td>\n<td><strong>Reference Price Level<\/strong><\/td>\n<td><strong>Key Driver<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Retest of 52 week high, Rs 220.36<\/td>\n<td>Strengths outlined above play out and sentiment improves<\/td>\n<\/tr>\n<tr>\n<td>Current Price<\/td>\n<td>Rs 215.39<\/td>\n<td>Present market price as of 3 Sep 2026<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Retest of 52 week low, Rs 132.30<\/td>\n<td>Risks outlined above dominate and sentiment weakens<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Using the stock&#8217;s own 52 week trading range as the reference band keeps both the Piramal Pharma bull case and the bear case anchored to real, observed price levels rather than a speculative external forecast.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Could_Tip_the_Balance_Between_the_Bull_and_Bear_Case\"><\/span><strong>What Could Tip the Balance Between the Bull and Bear Case<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The most direct signal to watch for Piramal Pharma is the next couple of quarterly results, since earnings trends will either support or undercut the Piramal Pharma bull case laid out above. A stretch of steady execution and stable sector conditions would strengthen the bull case, while any deterioration in the specific risks flagged in the bear case would tilt the balance the other way.<\/p>\n<p>Broader sector trends in pharmaceuticals and cdmo and overall market risk appetite are the other variables worth tracking through the rest of 2026.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Piramal_Pharma\"><\/span><strong>How to Invest in Piramal Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Investors weighing the Piramal Pharma bull case against the bear case can use the Univest Screener to check live fundamentals, valuation ratios and peer comparisons before making a decision.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Piramal Pharma Data<\/strong><\/a><\/p>\n<p>Start by opening a demat and trading account with a SEBI registered broker if you do not already have one active.<\/p>\n<p>Review Piramal Pharma&#8217;s quarterly results and sector trends to see which case the latest data supports.<\/p>\n<p>Weigh the Piramal Pharma bull case upside against the bear case downside relative to the current market price to gauge the risk to reward on offer.<\/p>\n<p>Size any position according to your own risk tolerance, since both scenarios discussed here are illustrative and not guaranteed outcomes.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Piramal Pharma bull case rests on the strengths outlined above playing out as earnings and sector conditions evolve, while the bear case reflects the risks that could keep the stock anchored closer to its 52 week low. Whether the Piramal Pharma bull case or the bear case plays out will likely become clearer over the next couple of quarters of results and sector data.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Piramal Pharma live price and get daily stock recommendations.<\/em><\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Piramal_Pharma_Bull_Case_vs_Bear_Case\"><\/span><strong>FAQs on Piramal Pharma Bull Case vs Bear Case<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Piramal_Pharma_bull_case_for_2026\"><\/span><strong>What is the Piramal Pharma bull case for 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Piramal Pharma bull case for 2026 is built on strong momentum near 52 week high and diversified pharma and cdmo portfolio, with the stock able to retest its 52 week high of Rs 220.36 if these strengths continue to play out.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Piramal_Pharma_bear_case_for_2026\"><\/span><strong>What is the Piramal Pharma bear case for 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Piramal Pharma bear case for 2026 centres on currently loss making and leveraged balance sheet, with the stock at risk of retesting its 52 week low of Rs 132.30 if these risks dominate.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Should_I_buy_Piramal_Pharma_share_now\"><\/span><strong>Should I buy Piramal Pharma share now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Piramal Pharma trades at Rs 215.39, and whether it fits your portfolio depends on how you weigh the Piramal Pharma bull case against the bear case risks discussed in this article, ideally after confirming with a SEBI registered financial advisor.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_in_the_Piramal_Pharma_bear_case\"><\/span><strong>What are the key risks in the Piramal Pharma bear case?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The key risks in the Piramal Pharma bear case include currently loss making, leveraged balance sheet and regulatory and quality compliance risk.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_catalysts_for_the_Piramal_Pharma_bull_case\"><\/span><strong>What are the main catalysts for the Piramal Pharma bull case?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The main catalysts for the Piramal Pharma bull case are strong momentum near 52 week high, diversified pharma and cdmo portfolio and global cdmo manufacturing footprint.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_track_Piramal_Pharma_share_price_live\"><\/span><strong>Where can I track Piramal Pharma share price live?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> You can track Piramal Pharma share price live on the Univest Screener, which shows CMP, volume, valuation ratios and other fundamentals updated through the trading session.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_52_week_high_and_low_of_Piramal_Pharma\"><\/span><strong>What is the 52 week high and low of Piramal Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The 52 week high of Piramal Pharma is Rs 220.36 and the 52 week low is Rs 132.30, with the stock currently trading at Rs 215.39.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_can_I_buy_Piramal_Pharma_shares\"><\/span><strong>How can I buy Piramal Pharma shares?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> You can buy Piramal Pharma shares through any SEBI registered stockbroker by placing an order on the NSE or BSE during market hours, after reviewing the company&#8217;s fundamentals and your own investment goals.<\/p>\n<div class=\"faq-schema\">\u00a0<\/div><p><\/p>","protected":false},"excerpt":{"rendered":"<p>Piramal Pharma bull case and bear case for 2026, based on CMP Rs 215.39, 52 week range Rs 132.30 to Rs 220.36, valuation and technical data.<\/p>\n","protected":false},"author":36,"featured_media":229627,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[3802],"class_list":["post-229628","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["229627"],"_edit_lock":["1788429531:36"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["24"],"rank_math_seo_score":["70"],"rank_math_title":["Piramal Pharma bull case"],"rank_math_description":["Piramal Pharma bull case and bear case for 2026, based on CMP Rs 215.39, 52 week range Rs 132.30 to Rs 220.36, valuation and technical data."],"rank_math_focus_keyword":["Piramal Pharma bull case"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_last":["36"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["41370"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/piramal-pharma-share-bull-case-vs-bear-case-2026.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/229628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=229628"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/229628\/revisions"}],"predecessor-version":[{"id":229756,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/229628\/revisions\/229756"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/229627"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=229628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=229628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=229628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}